title: [Indications and clinical use of sugammadex].
abstract: Sugammadex, a cyclodextrin, is a novel agent designed to encapsulate selectively steroidal neuromuscular blocking agents such as rocuronium and vecuronium as well. One molecule of sugammadex is able to encapsulate only one molecule of muscle relaxant. This original pharmacological property allows a very rapid reversal of muscle paralysis. After sugammadex injection, a train of four ratio higher than 0.9 is obtained in less than 5 minutes in all the patients whatever the degree of muscle paralysis at the time of reversal and even when anesthesia is maintained with halogenated agents. However, in order to preserve this efficacy, the dose of sugammadex needs to be adjusted to the degree of muscle paralysis at the time of reversal : 2 mg/kg after obtaining 2 responses at the adductor pollicis muscle after a train of four stimulation, 4 mg/kg with a post-tetanic count between 1 and 3 responses, and 12 to 16 mg/kg in case of rescue reversal (3 to 15 minutes after 0.6 to 1.2 mg/kg rocuronium). Even if the original property of sugammadex lets us think that per-operative neuromuscular transmission monitoring would not be furthermore useful, the assessment of the exact degree of muscle paralysis before reversal is mandatory for choosing the right dose of sugammadex.
authors.affiliation: Département d'Anesthésie Réanimation Chirurgicale, CHU de Poitiers, 2 rue de Milétrie, BP 577, 86021 Poitiers cedex, France. b.debaene@chu-poitiers.fr
authors.forename: B
authors.initials: B
authors.lastname: Debaene
authors.forename: C
authors.initials: C
authors.lastname: Meistelman
mesh_terms: D000465:Algorithms; D000732:Androstanols / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000494:pharmacology; D000762:Anesthesia Recovery Period; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004568:Electrodiagnosis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D009126:Muscle Relaxation / Q000187:drug effects; D009388:Neostigmine / Q000627:therapeutic use; D019148:Neuromuscular Blockade / Q000009:adverse effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000494:pharmacology; D011183:Postoperative Complications / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012133:Respiratory Paralysis / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D000077123:Rocuronium; D000077122:Sugammadex; D014673:Vecuronium Bromide / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000494:pharmacology; D047408:gamma-Cyclodextrins / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000732:Androstanols; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D009388:Neostigmine; D014673:Vecuronium Bromide; D000077123:Rocuronium